ArticlemBio2021
A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pooled it
- Association ofDiseases (Basel, Switzerland) · 2026Article
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- Calprotectin as a Biomarker for Infectious Diseases: A Comparative Review with Conventional Inflammatory Markers.International journal of molecular sciences · 2025Review
- Human immunity to fungal infections.The Journal of experimental medicine · 2025Review
- High nasopharyngeal and serum IL-6 levels and the - 573G > C polymorphism (rs1800796) are linked with the risk of severe COVID-19 in a Mexican population: a case‒control study.BMC infectious diseases · 2025Article
- The Regulatory Role of CTCF in IL6 Gene Transcription Assessed in Breast Cancer Cell Lines.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Impact ofBiomedicines · 2024Article
- The Interleukin-6 gene variants may protect against SARS-CoV-2 infection and the severity of COVID-19: a case-control study in a Moroccan population.BMC medical genomics · 2024Article
- Unwinding circular RNA's role in inflammatory pulmonary diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Inflammatory Polymorphisms (IL-6Viruses · 2024Article
- HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19.Emerging microbes & infections · 2023Article
- Enhancement of IL-6 Production Induced by SARS-CoV-2 Nucleocapsid Protein and Bangladeshi COVID-19 Patients' Sera.Viruses · 2023Article
- Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination.Vaccines · 2023Article
- Interleukin 6 and interferon gamma haplotypes are related to cytokine serum levels in dogs in an endemic Leishmania infantum region.Infectious diseases of poverty · 2023Article
- Association ofFrontiers in neuroscience · 2023Article
- Association between IL-6 polymorphisms and Atopic Dermatitis in Chinese Han children.Frontiers in pediatrics · 2023Article
- Dynamics of Viral and Host 3D Genome Structure upon Infection.Journal of microbiology and biotechnology · 2022Review
- Post-COVID Pain Is Not Associated with Inflammatory Polymorphisms in People Who Had Been Hospitalized by COVID-19.Journal of clinical medicine · 2022Article
- Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 1 country.
Tao Chen *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yu-Xin Lin *State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yan Zha *NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Ying SunState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jinxiu TianState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhiying YangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Shan-Wen LinYangjiang Key Laboratory of Respiratory Disease, Department of Respiratory Medicine, People's Hospital of Yangjiang, Yangjiang, Guangdong, China.
Fuxun YuNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Zi-Sheng ChenDepartment of Respiratory Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.
Bo-Hua KuangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jin-Ju LeiState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ying-Jie NieNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Yonghao XuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Dong-Bo TianDepartment of Respiratory Medicine, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China.
Ying-Zi LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Bin YangNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Qiang XuNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Li YangNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Nanshan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Meizhen ZhengDepartment of Biology, Southern University of Science and Technology, Shenzhen, China.
Yimin LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jincun ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiang-Yan ZhangNHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guizhou University, Guizhou, China.
Lin FengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID 0000-0001-6461-5838
Guizhou University · CNSun Yat-sen University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNThird Affiliated Hospital of Guangzhou Medical University · CNSouthern University of Science and Technology · CN
Funding
Fundamental Research Funds for Central Universities 19ykzd42Guangdong Zhong Nan-shan Medical Foundation ZNSA-2020001National Natural Science Foundation of China (NSFC) 81922049National Natural Science Foundation of China (NSFC) 81972163the Health & Medical Collaborative Innovation Project of Guangdong 201803040003
Abstract
Interleukin6 (IL-6) is a key driver of hyperinflammation in COVID-19, and its level strongly correlates with disease progression. To investigate whether variability in COVID-19 severity partially results from differential
Indexed as
A549 CellsCOVID-19GenotypeHaplotypesHeLa CellsHumansInterleukin-6Polymorphism, Single NucleotideReal-Time Polymerase Chain ReactionSoftwareIL6 protein, humanInterleukin-6COVID-19CTCFgenetic polymorphismsinterleukin-6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.